<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1427">
  <stage>Registered</stage>
  <submitdate>27/03/2003</submitdate>
  <approvaldate>27/03/2003</approvaldate>
  <actrnumber>ACTRN12606000327583</actrnumber>
  <trial_identification>
    <studytitle>The DINO Trial</studytitle>
    <scientifictitle>Docosahexaenoic Acid (DHA) for the Improvement of Neurodevelopmental Outcome in Preterm Infants.</scientifictitle>
    <utrn />
    <trialacronym>DINO</trialacronym>
    <secondaryid>Perinatal Trials Registry: PTR424</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Preterm Infants &lt; or = 32 weeks</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Childbirth and postnatal care</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1. High - DHA feeding practice: mothers diet supplemented with tuna oil capsules 6x 500mg DHA rich tuna oil capsules per day to increase DHA in breast milk. If formula is required a high DHA commercial preterm formula is used.
The intervention will commence within 5 days of the preterm infant commencing enteral feeds and continue until the expected term date (40 weeks post menstrual age). 
Follow up will occur at 4, 12 and 18 months corrected age.</interventions>
    <comparator>2. Standard infant feeding practice. Mothers take 6x500mg placebo soy oil capsules or standard preterm infant formula.</comparator>
    <control>Placebo</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Neurodevelopment assessed with the Bayleys Scales of Infant Development (II).</outcome>
      <timepoint>At 18 months corrected age</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The primary outcome for the follow-up study at seven years' corrected age is general intellectual ability (Full Scale IQ) as estimated with the Wechsler Abbreviated Scale of Intelligence (WASI). </outcome>
      <timepoint>Seven years' corrected age</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Growth</outcome>
      <timepoint>Will be measured weekly from enrolment until estimated date of delivery (EDD) and then at 4, 12 and 18 months corrected age.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety</outcome>
      <timepoint>Markers of safety, such as episodes of necrotising enterocolitis and days to reach full enteral feeds will be collected and assessed.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary outcomes include cognitive function, educational progress, behaviour, quality of life, symptoms of asthma and allergy, anthropometrics and blood pressure.  </outcome>
      <timepoint>Seven years' corrected age</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Infants born &lt; or = 32 weeks gestation 2. Signed written informed consent 3. Family/guardians who speak English</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>32</inclusivemaxage>
    <inclusivemaxagetype>Weeks</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Infants with major congenital or chromosomal abnormalities 2. More than 5 days after commencing enteral feeds 3. Lactating mother with blood clotting disorder where tuna oil is contraindicated or regularly taking anticoagulant therapy 4. Participation in other clinical trials involving fatty acid intervention 5. Geographic location 6. Multiple births where not all live born infants are eligible.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Centralised telephone randomisation service</concealment>
    <sequence>Computer generated randomisation schedule with balanced variable blocks, stratified by study site, gender and birthweight.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>23/12/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>497</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,WA,VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Health and Medical Research Council</primarysponsorname>
    <primarysponsoraddress>GPO Box 1421 Canberra ACT 2601</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council</fundingname>
      <fundingaddress>National Health and Medical Research Council GPO Box 1421 Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Docosahexaenoic Acid (DHA) is a long chain omega 3 polyunsaturated fatty acid which is important for growth and development. DHA also plays an essential role in the development of the central nervous system and retinal function in infants. Preterm infants are denied the large amount of DHA which is normally delivered via the placenta in the last trimester of pregnancy. The DINO trial is a multi-centre, randomized controlled trial to determine whether increasing the level of DHA in breast milk will improve the developmental outcome of preterm infants who are born less than 32 weeks gestation. Study participants, clinicians and trial personnel will be blinded to treatment allocation.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Children Yout and Women's Health Service</ethicname>
      <ethicaddress />
      <ethicapprovaldate>9/05/2002</ethicapprovaldate>
      <hrec>REC973/4/2005</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Flinders Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>9/05/2002</ethicapprovaldate>
      <hrec>122/023</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>King Edward Memorial Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>30/05/2003</ethicapprovaldate>
      <hrec>EC03-21.4</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Women's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>10/06/2003</ethicapprovaldate>
      <hrec>03/16</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospita</ethicname>
      <ethicaddress />
      <ethicapprovaldate>22/09/2003</ethicapprovaldate>
      <hrec>RWH03/16</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Carmel Collins</name>
      <address>Women's and Children's Health Research Institute
Flinders Medical Centre
Bedford Park SA  5042</address>
      <phone>+61 8 8204 5575</phone>
      <fax>+61 8 8204 6296</fax>
      <email>carmel.collins@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Carmel Collins</name>
      <address>Women's and Children's Health Research Institute
Flinders Medical Centre
Bedford Park SA  5042</address>
      <phone>+61 8 8204 5575</phone>
      <fax>+61 8 8204 6296</fax>
      <email>carmel.collins@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Carmel Collins</name>
      <address>Women's and Children's Health Research Institute
Flinders Medical Centre
Bedford Park SA  5042</address>
      <phone>+61 8 8204 5575</phone>
      <fax>+61 8 8204 6296</fax>
      <email>carmel.collins@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Maria Makrides</name>
      <address>Women's and Children's Health Research Institute
72 King William Road
North Adelaide  SA  5006</address>
      <phone>+61 8 8161 6179</phone>
      <fax>+61 8 8239 0267</fax>
      <email>maria.makrides@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>